Compare Devon Energy Corp (DVN) vs Dyne Therapeutics Inc. Common Stock (DYN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Dyne Therapeutics Inc. Common Stock — how do they compare? Devon Energy Corp trades at $50.03 (market cap $55.23B), while Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B). The key difference: Devon Energy Corp is far larger — about 19.3× Dyne Therapeutics Inc. Common Stock's market cap, and Devon Energy Corp pays a 2.55% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Dyne Therapeutics Inc. Common Stock for 0 Days on average.
| DVN | DYN | |
|---|---|---|
Market Cap | $55.23B | $2.86B |
Volume | 10,032,111 | 3,341,579 |
Sector | Energy | Health |
52-Week High | $52.07 | $26.78 |
52-Week Low | $31.74 | $14.60 |
Typical Hold Time | 136 Days | 0 Days |
Enterprise Value | $65.97B | $2.18B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $49.92, up 1.96% with strong bullish technical signals from moving averages. The stock shows attractive valuation metrics including a P/E of 10.92 and P/S of 1.79, while maintaining solid profitability with 16.67% net margins. Recent activist investor pressure for strategic alternatives and potential asset sales create catalysts, though the company faces earnings volatility with mixed quarterly results including a Q1 miss but Q2 beat.
DVN presents value opportunity with 25% upside to consensus target of $62.53, supported by 72% analyst buy ratings. Key risks include oil price sensitivity and execution on asset sales, while the improving cash flow trend and Permian Basin focus provide fundamental support. The combination of reasonable valuation and strategic optionality makes DVN compelling for energy investors.
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →
